13 years in the past, Uruguay grew to become the primary nation on the planet to formally legalise hashish for leisure (adult-use) functions. In December 2013, state-controlled hashish retail gross sales, house cultivation, and social golf equipment had been absolutely legalised by President José Mujica.
In contrast to the rising variety of nations internationally which have legalised a number of of those parts within the years since, this was not the results of a zeitgeist shifting in the direction of extra liberal drug insurance policies. It was a reluctant safety measure, rising from a area that, in Mujica’s personal phrases, was ‘dropping the battle in opposition to medication and criminality’.
On the time, the transfer was criticised each internationally and domestically. Raymond Yans, then president of the Worldwide Narcotics Management Board (INCB), accused Montevideo of ‘pirate attitudes’ and mentioned the federal government had ‘knowingly determined to interrupt universally agreed and internationally endorsed authorized provisions’ of the 1961 Single Conference on Narcotic Medication.
Greater than a decade later, knowledge from Uruguay and the rising variety of nations which have since reformed their hashish legal guidelines enable us to look at the influence of hashish liberalisation on public well being, and whether or not the critics have been confirmed appropriate.
A landmark overview of world hashish coverage
Final week, a brand new landmark ‘narrative overview’ revealed in The Lancet Psychiatry (vol 13: 615–26) synthesised 25 years of current analysis from the Americas, Europe, Africa, Oceania, and Asia, drawing on pure experiments created by coverage adjustments to evaluate what truly occurred in every case.
The examine, led by Professor Tom Freeman and Dr Rachel Lees Thorne on the College of Bathtub, who collaborated with 11 analysis establishments, sought to measure three outcomes: adjustments in hashish use prevalence, charges of hashish use dysfunction, and hospital admissions for psychiatric situations.
It supplies essentially the most complete worldwide evaluation ever carried out on what tends to accompany various kinds of hashish reform, illuminating constant patterns, however by no means claiming to ascertain causation.
Finally, it discovered that public well being outcomes are much less related to whether or not hashish is authorized, and way more with how the market is structured and controlled.
BofC Intelligence
EU Regulation Hub
Monitoring authorized standing, market entry, and regulatory developments throughout 28 European nations — with market knowledge from Prohibition Companions.
Discover the hub →
Business legalisation
Probably the most strong proof comes from North America, the place the info infrastructure is strongest. In Canada, past-12-month hashish use amongst adults aged 16 and over rose from 22% earlier than legalisation in 2018 to 27% by 2020, stabilising at 26% by 2023–24.
In Ontario between 2014 and 2021, emergency division visits for cannabis-induced psychosis rose 220.7%, a development that had begun earlier than legalisation however accelerated throughout the commercialisation section, as retail shops expanded and higher-potency merchandise entered the market.
In Colorado, hospitalisations for sufferers with comorbid psychosis and hashish use dysfunction rose from 3.4 to eight.5 per 100,000 following non-medical legalisation, with retail gross sales starting in 2014.
All through the US, the examine notes that the variety of individuals utilizing hashish on a day by day or near-daily foundation overtook these ingesting alcohol on the similar frequency ‘for the reason that mid-Nineteen Nineties and particularly after 2015’, a shift the authors regard as traditionally important.
On the psychiatric proof, the authors acknowledged: “There isn’t any constant proof for associations with the prevalence or incidence of psychotic problems, nevertheless, commercialised legalisation was related to a rise in hospital visits associated to psychosis, and psychotic problems comorbid with hashish use dysfunction.”
Managed legalisation fashions
Conversely, the info from nations with extra tightly managed markets confirmed little to no proof of elevated use.
In Uruguay, two research discovered both no important improve or reductions in past-year use, past-month use, and high-risk use amongst younger individuals aged 12–21 in contrast with a matched Chilean management group.
Germany’s interim analysis, revealed in September 2025, discovered no affiliation between its April 2024 legalisation and adjustments in hashish consumption throughout three inhabitants surveys.
One Swiss randomised managed trial, which assigned 378 members which randomly assigned 378 members both to an unlawful market management group, or a bunch that had authorized entry to hashish for non-medical functions, together with regulated hashish merchandise, safer use data, and voluntary counselling, discovered that hashish use dysfunction scores at six-month follow-up weren’t considerably totally different between two teams.
Information & Evaluation
Germany’s Hashish Reform Reveals No Indicators of Hurt its Critics Predicted, Authorities Mandated Information Reveals
On the second anniversary of Germany’s landmark Hashish Act (CanG) coming into power, essentially the most complete knowledge and evaluation of its influence to this point has been revealed. At present, the federal government […]
Learn the Story →
Within the UK, diminished enforcement between 2004 and 2009 produced no substantial change in use amongst adolescents or adults, whereas hospital admissions for cannabis-induced psychosis declined throughout the identical interval.
Nevertheless, the info from European states is thinner. Germany’s analysis covers solely months of a brand new framework, the Netherlands pilot has but to report findings. Switzerland’s randomised managed trial represents essentially the most methodologically strong European knowledge level to this point, however covers solely six months of follow-up.
As such, the authors stay cautious about drawing agency conclusions from these restricted knowledge units, suggesting the info factors to an absence of hurt, not a assured absence of hurt over time.
On medical hashish, now by far the dominant mannequin of entry to hashish all through the world, the authors elevate issues about poorly regulated markets.
For example, Australia has generated over 700,000 prescriber approvals throughout greater than 250 medical indications, many with restricted efficacy or security knowledge.
They conclude that authorized medical entry can present real profit when supported by ample proof, however that wider entry with out that basis could supply little profit whereas growing hurt.
Thailand
The starkest case examine within the overview is Thailand, which in 2022 grew to become the primary nation in Asia to legalise non-medical hashish, however has since reversed course.
Following legalisation, a fast commercialised proliferation of dispensaries drove a five-fold improve in sufferers recognized with cannabis-related problems.
Inpatient circumstances of cannabis-induced psychotic dysfunction rose from 477 in 2017 to 2,713 in 2023, hashish poisoning circumstances from 39 to 637, and acute hashish intoxications from 76 to 1,039 over the identical interval.
In June 2025, Thailand’s Ministry of Public Well being mandated a medical certificates for all hashish purchases from licensed retailers. The authors describe this as ‘an unprecedented take a look at of how a commercialised authorized marketplace for non-medical use is likely to be reversed.’
Grownup-Use
Thailand’s Grownup-Use Hashish Roll Again: From Laissez-Faire to Structured Framework
Earlier this month, Thailand’s Public Well being Minister Cholnan Srikaew proposed a brand new invoice that might successfully roll again the nation’s pioneering adult-use hashish legalisation. Within the newest instance of a […]
Learn the Story →
Conclusions
The overview’s central discovering is that the mannequin of legalisation issues as a lot as legalisation itself. Business legalisation, characterised by retail retailer proliferation and the sale of higher-potency merchandise, is persistently related to elevated hashish use and hashish use dysfunction amongst adults.
Tightly managed, non-commercial legalisation, as in Uruguay, was related to reductions in use amongst younger individuals and higher-risk person teams. Decriminalisation, throughout Europe, Africa, Oceania, and Asia, confirmed little to no affiliation with adjustments in use or psychiatric outcomes.
On psychosis, the image is extra nuanced. The paper finds no constant proof that hashish coverage adjustments the prevalence or incidence of psychotic problems within the normal inhabitants.
It does, nevertheless, discover that business legalisation is related to a rise in hospital visits associated to psychosis, and with psychotic problems comorbid with hashish use dysfunction.
Though these patterns seem persistently, the examine is a story overview of pure experiments. As such the findings are synthesised by means of finest obtainable proof from real-world coverage adjustments, reasonably than from managed scientific trials.
Because the authors acknowledge, causation can’t be established. What the overview demonstrates is affiliation between sure coverage buildings and sure outcomes. Whether or not these outcomes are pushed by authorized entry, by the business surroundings, by product traits, or by underlying social and demographic components that additionally formed the coverage resolution can’t be conclusively separated.
The proof base additionally has a geographic imbalance. The vast majority of high-quality analysis originates from the USA and Canada, limiting the generalisability of those findings to the numerous nations now weighing hashish reform.
“In a quickly altering world hashish coverage panorama it’s more and more essential to ask how coverage will change, reasonably than if it should change in any respect,” mentioned lead creator Daniel Freeman.
“The kind of coverage change is important. Different insurance policies, resembling decriminalisation or strictly regulated legalisation, can take away the harms of criminalising individuals who use hashish, whereas limiting adjustments in use.”
13 years in the past, Uruguay grew to become the primary nation on the planet to formally legalise hashish for leisure (adult-use) functions. In December 2013, state-controlled hashish retail gross sales, house cultivation, and social golf equipment had been absolutely legalised by President José Mujica.
In contrast to the rising variety of nations internationally which have legalised a number of of those parts within the years since, this was not the results of a zeitgeist shifting in the direction of extra liberal drug insurance policies. It was a reluctant safety measure, rising from a area that, in Mujica’s personal phrases, was ‘dropping the battle in opposition to medication and criminality’.
On the time, the transfer was criticised each internationally and domestically. Raymond Yans, then president of the Worldwide Narcotics Management Board (INCB), accused Montevideo of ‘pirate attitudes’ and mentioned the federal government had ‘knowingly determined to interrupt universally agreed and internationally endorsed authorized provisions’ of the 1961 Single Conference on Narcotic Medication.
Greater than a decade later, knowledge from Uruguay and the rising variety of nations which have since reformed their hashish legal guidelines enable us to look at the influence of hashish liberalisation on public well being, and whether or not the critics have been confirmed appropriate.
A landmark overview of world hashish coverage
Final week, a brand new landmark ‘narrative overview’ revealed in The Lancet Psychiatry (vol 13: 615–26) synthesised 25 years of current analysis from the Americas, Europe, Africa, Oceania, and Asia, drawing on pure experiments created by coverage adjustments to evaluate what truly occurred in every case.
The examine, led by Professor Tom Freeman and Dr Rachel Lees Thorne on the College of Bathtub, who collaborated with 11 analysis establishments, sought to measure three outcomes: adjustments in hashish use prevalence, charges of hashish use dysfunction, and hospital admissions for psychiatric situations.
It supplies essentially the most complete worldwide evaluation ever carried out on what tends to accompany various kinds of hashish reform, illuminating constant patterns, however by no means claiming to ascertain causation.
Finally, it discovered that public well being outcomes are much less related to whether or not hashish is authorized, and way more with how the market is structured and controlled.
BofC Intelligence
EU Regulation Hub
Monitoring authorized standing, market entry, and regulatory developments throughout 28 European nations — with market knowledge from Prohibition Companions.
Discover the hub →
Business legalisation
Probably the most strong proof comes from North America, the place the info infrastructure is strongest. In Canada, past-12-month hashish use amongst adults aged 16 and over rose from 22% earlier than legalisation in 2018 to 27% by 2020, stabilising at 26% by 2023–24.
In Ontario between 2014 and 2021, emergency division visits for cannabis-induced psychosis rose 220.7%, a development that had begun earlier than legalisation however accelerated throughout the commercialisation section, as retail shops expanded and higher-potency merchandise entered the market.
In Colorado, hospitalisations for sufferers with comorbid psychosis and hashish use dysfunction rose from 3.4 to eight.5 per 100,000 following non-medical legalisation, with retail gross sales starting in 2014.
All through the US, the examine notes that the variety of individuals utilizing hashish on a day by day or near-daily foundation overtook these ingesting alcohol on the similar frequency ‘for the reason that mid-Nineteen Nineties and particularly after 2015’, a shift the authors regard as traditionally important.
On the psychiatric proof, the authors acknowledged: “There isn’t any constant proof for associations with the prevalence or incidence of psychotic problems, nevertheless, commercialised legalisation was related to a rise in hospital visits associated to psychosis, and psychotic problems comorbid with hashish use dysfunction.”
Managed legalisation fashions
Conversely, the info from nations with extra tightly managed markets confirmed little to no proof of elevated use.
In Uruguay, two research discovered both no important improve or reductions in past-year use, past-month use, and high-risk use amongst younger individuals aged 12–21 in contrast with a matched Chilean management group.
Germany’s interim analysis, revealed in September 2025, discovered no affiliation between its April 2024 legalisation and adjustments in hashish consumption throughout three inhabitants surveys.
One Swiss randomised managed trial, which assigned 378 members which randomly assigned 378 members both to an unlawful market management group, or a bunch that had authorized entry to hashish for non-medical functions, together with regulated hashish merchandise, safer use data, and voluntary counselling, discovered that hashish use dysfunction scores at six-month follow-up weren’t considerably totally different between two teams.
Information & Evaluation
Germany’s Hashish Reform Reveals No Indicators of Hurt its Critics Predicted, Authorities Mandated Information Reveals
On the second anniversary of Germany’s landmark Hashish Act (CanG) coming into power, essentially the most complete knowledge and evaluation of its influence to this point has been revealed. At present, the federal government […]
Learn the Story →
Within the UK, diminished enforcement between 2004 and 2009 produced no substantial change in use amongst adolescents or adults, whereas hospital admissions for cannabis-induced psychosis declined throughout the identical interval.
Nevertheless, the info from European states is thinner. Germany’s analysis covers solely months of a brand new framework, the Netherlands pilot has but to report findings. Switzerland’s randomised managed trial represents essentially the most methodologically strong European knowledge level to this point, however covers solely six months of follow-up.
As such, the authors stay cautious about drawing agency conclusions from these restricted knowledge units, suggesting the info factors to an absence of hurt, not a assured absence of hurt over time.
On medical hashish, now by far the dominant mannequin of entry to hashish all through the world, the authors elevate issues about poorly regulated markets.
For example, Australia has generated over 700,000 prescriber approvals throughout greater than 250 medical indications, many with restricted efficacy or security knowledge.
They conclude that authorized medical entry can present real profit when supported by ample proof, however that wider entry with out that basis could supply little profit whereas growing hurt.
Thailand
The starkest case examine within the overview is Thailand, which in 2022 grew to become the primary nation in Asia to legalise non-medical hashish, however has since reversed course.
Following legalisation, a fast commercialised proliferation of dispensaries drove a five-fold improve in sufferers recognized with cannabis-related problems.
Inpatient circumstances of cannabis-induced psychotic dysfunction rose from 477 in 2017 to 2,713 in 2023, hashish poisoning circumstances from 39 to 637, and acute hashish intoxications from 76 to 1,039 over the identical interval.
In June 2025, Thailand’s Ministry of Public Well being mandated a medical certificates for all hashish purchases from licensed retailers. The authors describe this as ‘an unprecedented take a look at of how a commercialised authorized marketplace for non-medical use is likely to be reversed.’
Grownup-Use
Thailand’s Grownup-Use Hashish Roll Again: From Laissez-Faire to Structured Framework
Earlier this month, Thailand’s Public Well being Minister Cholnan Srikaew proposed a brand new invoice that might successfully roll again the nation’s pioneering adult-use hashish legalisation. Within the newest instance of a […]
Learn the Story →
Conclusions
The overview’s central discovering is that the mannequin of legalisation issues as a lot as legalisation itself. Business legalisation, characterised by retail retailer proliferation and the sale of higher-potency merchandise, is persistently related to elevated hashish use and hashish use dysfunction amongst adults.
Tightly managed, non-commercial legalisation, as in Uruguay, was related to reductions in use amongst younger individuals and higher-risk person teams. Decriminalisation, throughout Europe, Africa, Oceania, and Asia, confirmed little to no affiliation with adjustments in use or psychiatric outcomes.
On psychosis, the image is extra nuanced. The paper finds no constant proof that hashish coverage adjustments the prevalence or incidence of psychotic problems within the normal inhabitants.
It does, nevertheless, discover that business legalisation is related to a rise in hospital visits associated to psychosis, and with psychotic problems comorbid with hashish use dysfunction.
Though these patterns seem persistently, the examine is a story overview of pure experiments. As such the findings are synthesised by means of finest obtainable proof from real-world coverage adjustments, reasonably than from managed scientific trials.
Because the authors acknowledge, causation can’t be established. What the overview demonstrates is affiliation between sure coverage buildings and sure outcomes. Whether or not these outcomes are pushed by authorized entry, by the business surroundings, by product traits, or by underlying social and demographic components that additionally formed the coverage resolution can’t be conclusively separated.
The proof base additionally has a geographic imbalance. The vast majority of high-quality analysis originates from the USA and Canada, limiting the generalisability of those findings to the numerous nations now weighing hashish reform.
“In a quickly altering world hashish coverage panorama it’s more and more essential to ask how coverage will change, reasonably than if it should change in any respect,” mentioned lead creator Daniel Freeman.
“The kind of coverage change is important. Different insurance policies, resembling decriminalisation or strictly regulated legalisation, can take away the harms of criminalising individuals who use hashish, whereas limiting adjustments in use.”
Hashish Regulation Sources in Poland
Discover important authorized pages about hashish cultivation, gross sales, and medical product rules in Poland. These sources will information you thru permissions, certifications, and compliance necessities.
-
Polish News Registration and Interests of Cannabis Businesses
-
Permissions for Cannabis Sales in Poland
-
Authorization for Importing or Manufacturing Medical Products
-
Permission for Manufacturing or Importing Medical Products
-
Certificate of Good Manufacturing Practices (GMP)
-
Registration of Medical Products in Poland